AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC
AstraZeneca has submitted a new drug application (NDA) for the combination therapy of selpercatinib and Tagrisso for non‑small cell lung cancer, raising expectations for regulatory progress.